ClinicalTrials.gg
WithdrawnNCT02006173Updated Apr 29, 2016

Safety and Efficacy Study of Lidocaine Mixed Hyaluronate on Nasolabial Folds Correction

An interventional study of Lidocaine and Normal Saline in Nasolabial Folds Correction and Pain, sponsored by SciVision Biotech Inc.. Withdrawn at 1 site in Taiwan. Open to participants aged 30 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-04-29.

Sponsored by SciVision Biotech Inc. · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
30 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 204 studies testing lidocaine in Pain — 19 open to participants now, 19 under way, 1 of them phase 3. Lidocaine · Pain.

Enrollment
198th of 203
0 · median 66
No phase
79 of 204
9 open now
Registered
86th of 204
by date

Among the 204 studies testing lidocaine in Pain, this one is the 198th largest by enrollment of the 203 interventional ones that give a count, is one of 79 with no phase, and was the 86th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

19 of the 204 studies testing lidocaine in Pain are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About lidocaine

Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 30 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 204 studies testing lidocaine in Pain, or all of them as a file.
02

Study summary

This clinical trial is a double-blind, randomized, within-subject controlled, 2-armed, single-center study sponsored by SciVision Biotech Inc. and approved by National Taiwan University Hospital Research Ethics Committee. The aim of this post-marketing study is to evaluate the safety and efficacy of Hya-Dermis mixed with lidocaine, as well as the effectiveness of corrections of Hya-Dermis mixed with lidocaine. Accounting for potential loss to follow-up, the minimum enrollment was statistically determined to be 40 patients.

The study was estimated to be held one and half year including a 0-2 weeks screening period, a day of treatment, and follow-up at month 1, 3, 6, 9, 12. Patient informed consent forms will be obtained before the treatment. A pre-treatment photograph, nasolabial folds (NLF) severity scale scores, and individual aesthetic satisfaction will be the baseline. Two sets of randomized numbers are used, patient numbers and treatment numbers. Participants with odd patient numbers will be assigned to nasolabial group and those with even patient numbers will be assigned to nasolabial\&cheekbone group. Participants receive experiment treatment (Hya-Dermis mixed with lidocaine) in one side and control treatment (Hya-Dermis mixed with normal saline) in the other side of the face randomly depending on the treatment numbers. Both physicians and participants are only blind to the treatment assignment. 30 minutes after the injection, a post-photograph will be used to evaluate NLF severity scale scores and global aesthetic improvement scale (GAIS) by physicians. A questionnaire including the Visual Analog Scale (VAS) of pain during the treatment and individual aesthetic satisfaction will be collected from patients. The effectiveness analyses compare NLF severity scale scores and GAIS based on photograph records from physicians, as well as participant questionnaires for each group on every visit. The safety assessment evaluates any recorded adverse events following the device treatment.

03

Conditions studied

  • Nasolabial Folds Correction
  • Pain

Browse trials for

Keywords

  • Hya-Dermis mixed with lidocaine on reducing pain
04

Who can participate

Ages eligible
30 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 30 to 60 years of age and of any sex and willing to receive nasolabial folds correction by intradermal injection procedures
  • Have ability to understand and comply with the study requirements
  • Have approximately symmetrical nasolabial folds with a nasolabial folds severity score of 2-3 and the score difference between two sides is less 1
  • Agree to refrain from undergoing other anti-wrinkle treatments in the injective areas 12 months after the injections.
  • If female of , not be breastfeeding, have a negative urine pregnancy test on the treatment day and agree to use any approved or medically acceptable method of birth control throughout the study
  • Be willing to provide written prior to any procedures

Exclusion criteria

Exclusion Criteria:

  • Have history or active dermal diseases, inflammation, or any related disease, such as infection, psoriasis, and herpes.
  • Have history of coagulation defect diseases and still take aspirin, other anti-clotting, or blood activating medications 1 week before the treatments
  • Had permanent or semi-permanent implantation on nasolabial areas
  • Had dermal-related surgeries history (for example, laser, chemical dermabrasion, fraxel laser, thermocool) 6 months before the treatments.
  • Had facial wrinkles and folds corrections (for example, botox or other dermal fillers) 6 months before the study starts
  • Have a known history of allergic reactions like to hyaluronic acid
  • Have a known history of allergic reactions to lidocaine other local anesthesia
  • Have poor compliance with the study or follow-up schedule
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Normal saline

    Participants will be randomly assigned to nasolabial or nasolabial\&cheekbone group and receive control treatment (20mg/ml hyaluronic acid mixed with 0.175 ml normal saline) in one side of the face.

    Drug: Normal Saline

  • Active comparator
    Lidocaine

    Participants will be randomly assigned to nasolabial or nasolabial\&cheekbone group and receive experiment treatment (20mg/ml hyaluronic acid mixed with 0.175 ml 2% lidocaine) in one side of the face.

    Drug: Lidocaine

Interventions

  • Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia

    Also known as: Xylocaine

  • DrugNormal Saline
06

What researchers measure

Primary outcomes

  1. Pain Visual Analog Scale

    A quantification of the severity of pain experienced by individuals during the treatments. A scale of 100 mm horizontal line will be labeled by participants to assess pain on both sides of the injected areas 30 minutes after the treatment. The one on the extreme left (0) represents painless while the one on the extreme right (100) is set as the most pain could be imagined by participants.

    Time frame: 30 miuntes post-treatment

  2. Adverse events report

    Any adverse events and abnormal physical parameters or reports occurred and disappeared should be monitored throughout the trial. The records should be assessed and keep on track of the severity of individual adverse events and correlation with the treatment. Severity assessment: To assess the level of severity by rating 0 (none), 1 (mild), 2 (median), and 3 (sever). Correlation assessment: Physicians evaluate the impact of adverse events for each individual and determine their causality of the treatment. Based on the correlation with the treatment, giving score 0 (no correlated), 1 (low correlated), 2 (suspected correlated), 3 (most likely correlated). Adverse events tracking: Any adverse events should be reported to the physicians by participants. Physicians keep following up adverse events experienced participants until the event disappeared or the symptoms stabilized.

    Time frame: From date of treatment to 12 months

Secondary outcomes

  1. Nasolabial folds (NLF) severity scale

    Based on Skin Aging Atlas: Volume 2, Asian type photographs13, taking gender and NLF into consideration to quantify the degree of NLF severity. A validated 8-point photographic scale scored the severity grade from 0 (absent) to 7 (extreme) will be used to assess the severity of NLF at baseline, 30 minutes post-treatment, and every follow-up at 1, 3, 6, 9, 12 months.

    Time frame: From the baseline, 30 minutes post-treatment, to every follow-up at 1, 3, 6, 9, 12 months

  2. Global aesthetic improvement scale (GAIS)

    To quantify the level of overall aesthetic improvement 30 minutes after treatments and every follow-up at 1, 3, 6, 9, 12 months. A scale from 1 to 5 represent worse (1), no change (2), improved (3), much improved (4), and very much improved (5).

    Time frame: 30 minutes post-treatments and follow-ups at 1, 3, 6, 9, 12 months

  3. Aesthetic satisfaction questionnaire

    Subjects subjectively assessed overall satisfaction of general appearance toward the effectiveness of the treatment by rating 1 (not at all satisfied), 2 (not satisfied), 3 (neither satisfied nor dissatisfied), 4 (somewhat satisfied), and 5 (highly satisfied).

    Time frame: From the baseline, 30 minutes post-treatment, to every follow-up at 1, 3, 6, 9, 12 months

07

Study locations

1 site
  • Department of Dermatology, National Taiwan University Hospital
    Taipei, 10048, Taiwan
08

References and documents

Publications

  • Beer K, Beer J. Overview of facial aging. Facial Plast Surg. 2009 Dec;25(5):281-4. doi: 10.1055/s-0029-1243075. Epub 2009 Dec 18. PubMed 20024868 ↗
  • Sveikata K, Balciuniene I, Tutkuviene J. Factors influencing face aging. Literature review. Stomatologija. 2011;13(4):113-6. PubMed 22362337 ↗
  • Albert AM, Ricanek K Jr, Patterson E. A review of the literature on the aging adult skull and face: implications for forensic science research and applications. Forensic Sci Int. 2007 Oct 2;172(1):1-9. doi: 10.1016/j.forsciint.2007.03.015. Epub 2007 Apr 16. PubMed 17434276 ↗
  • Mendelson B, Wong CH. Changes in the facial skeleton with aging: implications and clinical applications in facial rejuvenation. Aesthetic Plast Surg. 2012 Aug;36(4):753-60. doi: 10.1007/s00266-012-9904-3. Epub 2012 May 12. PubMed 22580543 ↗
  • Romagnoli M, Belmontesi M. Hyaluronic acid-based fillers: theory and practice. Clin Dermatol. 2008 Mar-Apr;26(2):123-59. doi: 10.1016/j.clindermatol.2007.09.001. PubMed 18472056 ↗
  • van Eijk T, Braun M. A novel method to inject hyaluronic acid: the Fern Pattern Technique. J Drugs Dermatol. 2007 Aug;6(8):805-8. PubMed 17763611 ↗
  • Colatsky TJ. Mechanisms of action of lidocaine and quinidine on action potential duration in rabbit cardiac Purkinje fibers. An effect on steady state sodium currents? Circ Res. 1982 Jan;50(1):17-27. doi: 10.1161/01.res.50.1.17. No abstract available. PubMed 6274542 ↗
  • Smith L, Cockerham K. Hyaluronic acid dermal fillers: can adjunctive lidocaine improve patient satisfaction without decreasing efficacy or duration? Patient Prefer Adherence. 2011 Mar 14;5:133-9. doi: 10.2147/PPA.S11251. PubMed 21448297 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02006173
Lead sponsor
SciVision Biotech Inc.
Responsible party
Sponsor
First posted
Dec 10, 2013
Primary completion
Jul 2015
Last update
Apr 29, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion